The health insurance companies involved pursue the goal of working with all suitable pharmaceutical entrepreneurs

to conclude discount contracts according to § 130a paragraph 8 of the German Civil Code V for the active substance etanercept. The contract is concluded

within the framework of the open house biology process of health insurance companies:

Individual negotiations on contract content are not conducted, uniform conditions apply. The

Health insurance companies do not assure individual contracting partners exclusivity. The contract period is maximum

24 months starting from 01.10.2021. (Deviating from this, start at HKK only on April 1, 2022). The contract ends no later than September 30, 2023, regardless of

Date of conclusion of contract. All further information is available in the participation and contract documents for

take it out. If patent expires before 30.09.2023, the contract automatically ends at the end of the month of

patent expiration.

It is possible to join this open house biological process at any time within the contract period.

Due to the existence of industrial property rights with regard to the subject of the contract

Participation and contract documents will only be used to such pharmaceutical entrepreneurs

which offer/place on the market medicinal products for the active substance in question

or make it credible to the TK that medicinal products become the active substance in question within

to offer/place on the market of the contract period.

With all pharmaceutical entrepreneurs who have the requirements of Appendix 4 to the contract

(self-declaration of admission and to the company) and do so electronically in accordance with § 126a

Confirm the German Civil Code, a contract is concluded.

This publication does not concern the award of a public contract within the meaning of

Procurement Law Directive (2014/24/EC) or antitrust procurement law. In the interest of a broadest possible

information of interested pharmaceutical entrepreneurs will be informed in the

Supplement to the Official Journal of the European Union. The process name “open procedure” used in the context of this publication text in accordance with section IV.1.1) and the indication of

award criteria according to section II.2.5) are owed to the specifications of the announcement form and

have no further meaning. With this and with the use of the medium “TED” there is no submission

linked under public procurement regulations whose validity is not valid by law or procurement regulations

is compulsory.